Sales force deployment, brand and marketing-spend monitoring, HCP prescription behaviour, medical communication tracking, and generic launch readiness — built from stakeholder interviews, not guesswork.
Headcount, structure and coverage by department and region. India studies go deeper — hierarchy, salary and incentive structures, call frequency, and trade vs. institutional positioning.
Activity-by-activity reconstruction of a competitor's marketing execution and spend, sourced from pharma professionals, HCPs, distributors and chemists.
How prescribers are actually engaging with a brand, and how communication and field activity connect to it.
Continuous tracking across R&D/manufacturing, regulatory filings and supply chain to flag how close a generic threat really is — not a single snapshot.
Generic product launch and entry strategy, and go-to-market planning informed by the same competitive intelligence.
Positioning and pricing strategy grounded in what competitors are actually doing, not just published list prices.
Customer purchase behaviour, key purchase and switching criteria, and channel strategy across trade and institutional segments.
Mapping who actually drives purchase and prescribing decisions, alongside HCP behaviour tracking.
Sales force benchmarking across the US and EU, brand monitoring in India, and 18-month generic-launch tracking — see how this plays out in practice.
View case studies & insights